The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis
Der optimale PD-L1-Combined-Positive-Score-Schwellenwert zur Vorhersage des Nutzens von PD-1-Antikörper plus Chemotherapie bei Patient:innen mit HER2-negativem Magenadenokarzinom: Meta-Analyse
Cancer Immunology, Immunotherapy · 16.05.2024 · 73 (7)
DOI: 10.1007/s00262-024-03726-1 ↗Auf einen Blick
Sechs Phase-III-Studien mit 5.242 Patient:innen zeigen einen Nutzen von ICIs plus Chemotherapie gegenüber Chemotherapie allein. Der optimale CPS-Schwellenwert lag bei ≥ 5 für OS und ≥ 10 für PFS.
Fragestellung
Welcher PD-L1-CPS-Schwellenwert sagt den Nutzen von PD-1-Antikörper plus Chemotherapie bei metastasiertem HER2-negativem Magen-/GEA-Adenokarzinom am besten voraus?
Methode
Metaanalyse randomisierter Phase-III-Studien zu ICIs plus Chemotherapie versus Chemotherapie allein bei metastasiertem GEAC; gepoolte HR-Analysen nach PD-L1-Expression.
Ergebnisse
6 Studien mit 5.242 Patient:innen. OS verbessert: HR 0,79 (95 %-KI 0,72–0,86) global; 0,75 (0,57–0,98) asiatisch. PFS verbessert: HR 0,74 (0,68–0,82) global; 0,64 (0,56–0,73) asiatisch.
Schlussfolgerung der Autor:innen
Der Nutzen von ICIs plus Chemotherapie war bei asiatischen und globalen GEAC-Patient:innen ähnlich. Bei CPS < 5 oder < 10 könnten laut Autor:innen keine signifikanten Vorteile bestehen.
Kernaussagen
- ICIs plus Chemotherapie verbesserten OS und PFS gegenüber Chemotherapie allein.
- Der optimale CPS-Schwellenwert lag bei ≥ 5 für OS und ≥ 10 für PFS.
- CPS < 5 bzw. < 10 war mit keinem signifikanten Nutzen assoziiert.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 16.05.2024. Verfasst von Ji-Bin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen Un…. Hauptthemen laut MEDLINE: Stomach Neoplasms, B7-H1 Antigen, Immune Checkpoint Inhibitors, Adenocarcinoma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China-Guangdong Joint Fund, Guangdong Esophageal Cancer Research Institute, Wu Jieping Medical Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become the first-line treatment of metastatic gastric and gastroesophageal adenocarcinomas (GEACs). This study aims to figure out the optimal combined positive score (CPS) cutoff value.
Methods
We searched for randomized phase III trials to investigate the efficacy of ICIs plus chemotherapy for metastatic GEACs compared with chemotherapy alone. Pooled analyses of hazard ratios (HRs) based on PD-L1 expression were performed.
Results
A total of six trials (KEYNOTE-062, KEYNOTE-590, KEYNOTE-859, ATTRACTION-04, CheckMate 649, and ORIENT-16) were included, comprising 5,242 patients. ICIs plus chemotherapy significantly improved OS (HR: 0.79, 95% CI 0.72–0.86 in global patients; HR: 0.75, 95% CI 0.57–0.98 in Asian patients) and PFS (HR: 0.74, 95% CI 0.68–0.82 in global patients; HR: 0.64, 95% CI 0.56–0.73 in Asian patients) compared with chemotherapy alone. The differences in OS (ratio of HR: 1.05, 95% CI 0.79–1.40; predictive value: − 5.1%) and PFS (ratio of HR: 1.16, 95% CI 0.98–1.36; predictive value: − 13.5%) were not statistically significant between the global and Asian patients. Subgroup analyses indicated that the optimal CPS threshold was at ≥ 5 for OS and ≥ 10 for PFS with the highest predictive values.
Conclusions
The benefit derived from ICIs plus chemotherapy is similar between Asian and global GEAC patients. However, those with a PD-L1 CPS < 5 or CPS < 10 may not have significant benefits from ICIs therapy. Therefore, it is advisable to routinely assess PD-L1 expression in GEAC patients considered for ICIs treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, Peo…
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, Peop…
- Department of Medical Records, The First Affiliated Hospital, Sun Yat‑Sen University, Guangzhou, People's Republic of China.
- School of Public Health, Sun Yat-Sen University, Guangzhou, People's Republic of China.
- Center for Biomedical Information Technology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China.
Förderung
- National Natural Science Foundation of China-Guangdong Joint Fund
- Guangdong Esophageal Cancer Research Institute
- Wu Jieping Medical Foundation
Zitieren
APA
Li, J. B., Lai, M. Y., Lin, Z. C., Guan, W. L., Sun, Y. T., Yang, J., Wang, W. X., Yang, Z. R., & Qiu, M. Z. (2024). The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis. Cancer Immunology, Immunotherapy, 73(7). https://doi.org/10.1007/s00262-024-03726-1
Vancouver
Li JB, Lai MY, Lin ZC, Guan WL, Sun YT, Yang J, et al. The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis. Cancer Immunology, Immunotherapy. 2024;73(7). doi:10.1007/s00262-024-03726-1
BibTeX
@article{Li2024,
author = {Li, Ji-Bin and Lai, Ming-Yu and Lin, Zhuo-Chen and Guan, Wen-Long and Sun, Yu-Ting and Yang, Jing and Wang, Wen-Xuan and Yang, Zhi-Rong and Qiu, Miao-Zhen},
title = {The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
volume = {73},
number = {7},
doi = {10.1007/s00262-024-03726-1}
}
EUVIMED